SAPIEN 3 TAVR is proven superior* for low-surgical risk patients across outcomes that matter most to your low-risk patients1,2

TAVR offers many benefits that appeal to symptomatic severe aortic stenosis (SAS) patients, independent of surgical risk

When you treat every symptomatic severe AS patient like family, you want them to have a better treatment experience. Help them discover the quality of life benefits from TAVR treament and resume their everyday lives faster than surgery.1,2

In PARTNER 3 Trials, low-risk patients—and their families—spent less time in hospitals while recovering from the TAVR procedure.2,3

* The PARTNER 3 TRIAL, SAPIEN 3 TAVR proven superior to surgery on the primary endpoint all-cause death, all stroke, and rehabilitation and multiple pre-specified secondary endpoints.
Rehospitilization (valve-related or procedure-related and inclduing heart failure).
** Excludes multiplicity adjustment.


Talking to your patients about the benefits of TAVR can alleviate hesitations about valve replacement

SAVR

TAVR

Available for all surgical risk patients (except prohibitive risk)4
Available for severe, symptomatic calcific aortic stenosis patients, independent of surgical risk
More invasive procedure2
Less invasive procedure9
Requires sternotomy2
The most common approach is the transfemoral approach9
Requires stopping the heart and connecting the patient to a blood-pumping machine2
Does not require stopping the heart9
Requires general anesthesia
May be performed using conscious sedation
On average, may last ~3 hours*
On average, may last ~1 hour*
Average hospital stay may be 7 days*
Average hospital stay may be 3 days*

or

* The PARTNER 3 TRIAL, transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis.2

Utilize this patient tool to help guide the conversation. Download chart

Recommended resources

See all resources

Help your patients get back to their daily lives faster

References:   1. Leon MB, Mack MJ. PARTNER 3: transcatheter or surgical aortic valve replacement in low risk patients with aortic stenosis. Presented at ACC 2019; March 2019; New Orleans, LA. 2. Mack MJ, Leon MB, Thourani VH. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695-1705. 3. The Partner 3 Trial Clinical Study Report; April 2019. 4. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused guidelines of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary. J Am Coll Cardial. 2017;35(25):e1159-e1195.